Neuromed lands $53.3M in fifth round
|
VENTURE CAPITAL |
|||
|
COMPANY |
AMOUNT/ROUND |
LEAD INVESTORS |
DESCRIPTION |
|
Neuromed Pharmaceuticals
|
$53.3M
|
MPM Capital, James Richardson & Sons, Neuro Discovery, GrowthWorks Capital, BDC Venture Capital, CMDF, and the Royal Bank of Canada |
Much of that money is earmarked for clinical trials, including a late-stage study of a newly licensed pain drug. |
|
Nereus Pharmaceuticals
|
$45M
|
BankInvest Biomedical Venture |
The money will be drawn down in two tranches and used to complete Phase I and begin Phase II clinical trials for Nereus' two drug candidates. |
|
NeurAxon
|
$32M
|
Delphi Ventures and OrbiMed Advisors |
The money is earmarked for advancing the developer's pain therapies. |
|
Ophthotech
|
$36M
|
SV Life Sciences |
Ophthotech is off and running with a first round of $36 million |
|
Pevion Biotech
|
$30.2M
|
BZ Bank Aktiengesellschaft |
The company said it will use the funds to push a hepatitis C and breast cancer vaccines into Phase II. It will also fund preclinical vaccine candidates against RSV and Candida infections into clinical development. |
|
Topigen Pharmaceuticals
|
$25M
|
NovaQuest and MMV Financial |
The investment is earmarked for Phase II clinical programs relating to its lead products, TPI 1020, a small-molecule drug in development for Chronic Obstructive Pulmonary Disease and TPI ASM8, its RNA-inhibiting therapeutic for asthma. |
|
FoldRx
|
$22M
|
Cystic Fibrosis Foundation |
FoldRx has snagged $22 million from the Cystic Fibrosis Foundation to develop and commercialize new drugs for the condition. |